m3taversal
76e81ea220
- What: first divergence instances — AI labor displacement (cross-domain), GLP-1 economics (health), prevention-first cost dynamics (health), futarchy adoption (internet-finance), human-AI clinical collaboration (health) - Why: divergences are the game mechanic — no instances means no game. All 5 surfaced from genuine competing claims with real evidence on both sides. - Connections: each divergence includes "What Would Resolve This" research agenda as contributor hook Pentagon-Agent: Leo <A3DC172B-F0A4-4408-9E3B-CF842616AAE1>
55 lines
4.3 KiB
Markdown
55 lines
4.3 KiB
Markdown
---
|
|
type: divergence
|
|
title: "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?"
|
|
domain: health
|
|
description: "These are opposite cost problems from the same drug class — one assumes lifelong use drives inflation, the other shows 85% discontinuation undermines the chronic model. The answer determines payer strategy, formulary design, and the health domain's cost trajectory claims."
|
|
status: open
|
|
claims:
|
|
- "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"
|
|
- "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md"
|
|
surfaced_by: leo
|
|
created: 2026-03-19
|
|
---
|
|
|
|
# Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?
|
|
|
|
The KB holds two claims about GLP-1 economics that predict opposite problems from the same drug class. Both are backed by large datasets. Both are rated `likely`. They can't both be right about the dominant cost dynamic.
|
|
|
|
The inflationary claim assumes chronic use at $2,940+/year per patient creates unsustainable cost growth through 2035. The model depends on patients staying on treatment indefinitely — the "chronic use model" in the title.
|
|
|
|
The persistence claim shows that assumption doesn't hold: real-world data from 125,000+ commercially insured patients shows 85% discontinue by two years for non-diabetic obesity. If most patients don't sustain use, the chronic cost model breaks — but so does the therapeutic benefit.
|
|
|
|
## Divergent Claims
|
|
|
|
### Chronic use makes GLP-1s inflationary through 2035
|
|
**File:** [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
|
**Core argument:** Lifelong treatment at current pricing creates unsustainable spending growth. The chronic model means costs compound annually.
|
|
**Strongest evidence:** Category launch size ($50B+ projected), $2,940/year per patient, CBO/KFF cost modeling.
|
|
|
|
### Low persistence undermines the chronic use assumption
|
|
**File:** [[glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics]]
|
|
**Core argument:** 85% of non-diabetic obesity patients discontinue by year 2. The chronic model doesn't reflect real-world behavior.
|
|
**Strongest evidence:** JMCP study of 125,000+ commercially insured patients; semaglutide 47% one-year persistence vs 19% liraglutide.
|
|
|
|
## What Would Resolve This
|
|
|
|
- **Medicare persistence data:** Do Medicare populations (older, sicker, lower OOP after IRA cap) show better persistence than commercial populations?
|
|
- **Behavioral support impact:** Does combining GLP-1s with structured behavioral support (WHO recommendation, BALANCE Model) materially change dropout rates?
|
|
- **Cost per QALY at real-world persistence:** What's the actual cost-effectiveness when modeled with 15% two-year persistence rather than assumed chronic use?
|
|
- **Generic entry timeline:** Do biosimilar/generic GLP-1s at lower price points change the persistence equation by reducing OOP burden?
|
|
|
|
## Cascade Impact
|
|
|
|
- If chronic costs dominate: Vida's healthcare cost trajectory claims hold. Payer strategy must focus on formulary controls and prior authorization.
|
|
- If low persistence dominates: The inflationary projection is overstated. The real problem is wasted therapeutic investment and weight regain cycles. Payer strategy shifts to adherence support.
|
|
- If population-dependent: Both are right for different patient segments. The divergence dissolves into scope — diabetic patients may persist while obesity-only patients don't.
|
|
|
|
---
|
|
|
|
Relevant Notes:
|
|
- [[lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence]] — affordability as persistence driver
|
|
- [[semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x]] — drug-specific variation
|
|
- [[glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints]] — multi-organ value complicates pure cost analysis
|
|
|
|
Topics:
|
|
- [[_map]]
|